Experiments conducted in triplicate have confirmed that COTI-2 has a profound effect on caspase-9 activation through inhibition of Akt/PKB. According to the company, the resulting activation of caspase-9 leads to a vigorous apoptosis or programmed cell death in cancer cells.
Wayne Danter, president and CSO of Critical Outcome Technologies, said: “The confirmation of a novel mechanism of action for COTI-2 represents a significant advancement for Critical Outcome Technologies (COTI) and our anti-cancer drug development program.”